Edition:
United Kingdom

CSPC Pharmaceutical Group Ltd (1093.HK)

1093.HK on Hong Kong Stock

17.60HKD
4:48am BST
Change (% chg)

HK$-0.02 (-0.11%)
Prev Close
HK$17.62
Open
HK$17.80
Day's High
HK$18.14
Day's Low
HK$17.22
Volume
20,378,922
Avg. Vol
36,687,104
52-wk High
HK$26.75
52-wk Low
HK$11.98

Chart for

About

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and... (more)

Overall

Beta: 0.81
Market Cap(Mil.): HK$81,366.01
Shares Outstanding(Mil.): 6,054.02
Dividend: 0.12
Yield (%): 0.89

Financials

  1093.HK Industry Sector
P/E (TTM): 34.12 30.93 32.76
EPS (TTM): 0.39 -- --
ROI: 22.47 15.07 14.61
ROE: 23.81 16.59 16.33

BRIEF-CSPC Pharmaceutical Announces A Product Licensing Agreement

* UNIT ENTERED PRODUCT LICENSING AGREEMENT WITH GALAXY BIO, INC. FOR LICENSING & COMMERCIALIZATION OF "PACLITAXEL FOR INJECTION"

18 Apr 2018

BRIEF-CSPC Pharmaceutical Group Says Cancer Drug Approved By China FDA

* "VINORELBINE TARTRATE LIPOSOME INJECTION" GRANTED CLINICAL TRIAL APPROVAL BY CHINA FOOD AND DRUG ADMINISTRATION OF PRC Source text for Eikon: Further company coverage:

16 Apr 2018

BRIEF-CSPC Pharmaceutical Group's Drug Gets Approval By China FDA

* GRANTED APPROVAL BY CHINA FDA FOR PASSING CONSISTENCY OF QUALITY AND EFFICACY EVALUATION OF GENERIC DRUGS

12 Apr 2018

BRIEF-CSPC Pharmaceutical Group Says ‍Cancer Drug Granted Drug Clinical Trial Approval By China FDA

* ‍CANCER DRUG DEVELOPED BY WUHAN YZY BIOPHARMA​ GRANTED DRUG CLINICAL TRIAL APPROVAL BY CHINA FDA Source text for Eikon: Further company coverage:

16 Mar 2018

Earnings vs. Estimates